View clinical trials related to Healthy Participants.
Filter by:The main goal of this trial is to learn about the effect of Lu AG06474 on a battery of Evoked Pain Tests when a single dose is given to healthy adult participants. The effects of Lu AG06474 will be compared with 2 approved pain-relieving medications (ibuprofen and pregabalin) and with a placebo (a treatment that looks like the trial treatment but does not have any medicine in it). Each participant will receive 1 dose of each of these treatments during the trial (Lu AG06474, ibuprofen, pregabalin, and placebo), with 1 week between treatments. All treatments will be taken orally (by mouth), either as a liquid or a capsule.
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions and a single subcutaneous (SC) injection of AK006. The study will be conducted in 4 parts: a single-ascending dose part (Part A) in healthy participants, a multiple-ascending dose part (Part B) in healthy participants with an expanded cohort (Part C) in participants with chronic spontaneous urticaria (CSU), and a single ascending dose SC injection cohort (Part D) in healthy participants.
NNC0113-6856 is a new medicine which may help participants with type 2 diabetes to improve blood sugar control. NNC0113-6856 is slowly converted in the body to semaglutide, a substance similar to a hormone (signaling substance) in the body. The main purpose of this study will be to evaluate the safety of different strengths of NNC0113-6856 when given as multiple administrations, and the amount of NNC0113-6856 in the blood will be measured as well as the amount of specific parts (including semaglutide). Participants will either get multiple doses of the new medicine NNC0113-6856 or multiple doses of placebo (a "dummy" medicine that looks like the new medicine but is without any active ingredient). Whether participants get the new medicine or placebo is decided by chance. The duration of the study could last up to 25 weeks.
The purpose of this study is to investigate the safety of multiple oral doses of Lu AG06474, how well the doses are tolerated, and what the body does to the drug after administering it to healthy young participants. This study also aims to compare how the body absorbs and uses Lu AG06474 when it is given in capsule form versus when it is given as an oral solution.
The goal of this feasibility study is to evaluate a new sample preparator called See.d. After blood processing the instrument will produce a set of slides and a tube of plasma. These outputs could be used in further analysis in liquid biopsy applications.
The distinction between self-generated and external information is impaired in patients with schizophrenia, who are assumed to confuse imagination with real perceptions. To better understand the underlying mechanisms of these abnormalities, the investigator will investigate the brain mechanisms supporting auditory externalization. Auditory externalization is the ability to perceive whether a sound comes from inside or outside oneself. Our study, in healthy participants, will use functional brain imaging to identify the brain areas involved in the externalization of sound sources and to test whether neuromodulation of this area can modify this ability and provide a therapeutic lead in pathological populations
The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060. Rabeprazole belongs to a type of medications called proton pump inhibitors. In reality, some patients may take both PF-07220060 and rabeprazole together. This study is seeking participants that are: - Healthy male or female aged 18 to 65 years Participants in this study will receive PF-07220060 once or twice by mouth. The participants may receive different tablets for PF-07220060. Some participants will take a meal before receiving PF-07220060. In addition, some participants will take rabeprazole by mouth for 7 days before taking PF-07220060. The study will compare experiences of people receiving different formulations of PF-07220060. Experiences of people taking food and rabeprazole with PF-07220060 will be compared to those on PF-07220060 alone. This will help understand how much PF-07220060 is taken up into the blood. It will also help understand how meal and Rabeprazole medicine changes the uptake of PF-07220060 into the blood. Participants will take part in the study for a maximum of 74 days. During this time, they will have to stay onsite for 5 to 13 days. There will be up to 2 onsite study visits.
This study will consist of 2 parts. The study will evaluate whether administration of phenytoin impacts the single-dose drug levels of afimetoran and BMT-271199 (Part 1) and will evaluate whether multiple administrations of afimetoran impact the drug levels of midazolam and 1-hydroxymidazolam (Part 2).
The purposes of this study are to: - Learn about the safety and tolerability of CK 4021586 after a single dose and multiple doses in healthy subjects. - Find out how much CK-4021586 is in the blood after a single dose and multiple doses. - Determine the effect different doses of CK-4021586 on the pumping function of the heart. - Determine the effect of food in the stomach on how much CK-4021586 is in the blood after a single dose.
The goal of this clinical trial is to investigate the effects of kinesthetic motor imagery training and dual-task training on cognitive and motor functions in healthy young people. The main question[s] it aims to answer are: - Kinesthetic motor imagery training and dual-task training do not affect cognitive and motor functions in healthy young people. - Kinesthetic motor imagery training and dual-task training affect cognitive and motor functions in healthy youth. - In healthy young people, kinesthetic motor imagery training is more effective on cognitive functions than dual-task training. - In healthy young people, dual task training is more effective on motor functions than kinesthetic motor imagery training. Participants will be divided into 3 groups, taking into account the inclusion and exclusion criteria. Participants in each group will be asked to fill out the sociodemographic form before starting the training. Then, initial assessments were the Motion Image Questionnaire-3 to measure motor imagery ability, and the Box and Block Test for mental stopwatch; Stroop Test to measure cognitive functions; In order to evaluate the dual-task performance, the measurement of the dual-task effect and the Berg Balance scale, which evaluates balance as a motor function, and the Y test, which is frequently used in healthy individuals, will be applied. In the balance exercises group, the participants will do the determined balance exercises 3 days a week for 6 weeks, accompanied by a physiotherapist. In the double-task training group, the participants will perform the cognitive tasks in addition to the determined balance exercises, 3 days a week for 6 weeks, accompanied by a physiotherapist. In kinesthetic motor imagery group, the participants will do the physically determined balance exercises in the first session. Participants will participate in imagery exercises, 3 sessions a week for 6 weeks. Visualization studies will be performed in a quiet environment with the eyes closed, accompanied by a physiotherapist, and whether the participants perform a real motor imagery will be examined by evaluating their autonomic functions. At the end of 6 weeks, initial evaluations will be repeated in all groups. The investigators will compare dual-task training group, kinesthetic motor imagery training group and balance exercises group to see if changes in cognitive and motor function.